Outcomes of Adding Induction Chemotherapy to Concurrent Chemotherapy for Nasopharyngeal Carcinoma Patients with Moderate-Risk in the Intensity-Modulated Radiotherapy Era

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.v68.6
   PubMed Web of Science ®Google Scholar
• Wee JT, Ha TC, Loong SL, Qian CN. Is nasopharyngeal cancer really a “Cantonese cancer”? Chin J Cancer. 2010;29(5):517–526. doi:10.5732/cjc.009.10329
   PubMedGoogle Scholar
• Pfister DG, Spencer S, Adelstein D, et al. Head and neck cancers. Natl Compr Cancer Net. 2019.
   Google Scholar
• Sun X, Su S, Chen C, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol. 2014;110(3):398–403. doi:10.1016/j.radonc.2013.10.020
   PubMed Web of Science ®Google Scholar
• Yang Q, Cao SM, Guo L, et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer. 2019;119:87–96. doi:10.1016/j.ejca.2019.07.007
   PubMed Web of Science ®Google Scholar
• Sun Y, Li W, Chen N, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a Phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509–1520. doi:10.1016/S1470-2045(16)30410-7
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen L, Hu G, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. New Engl J Med. 2019;381:1124–1135. doi:10.1056/NEJMoa1905287
   PubMed Web of Science ®Google Scholar
• Tan T, Lim WT, Fong KW, et al. Concurrent chemo-radiation with or without induction gemcitabine, carboplatin, and paclitaxel: a randomized, Phase 2/3 trial in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2015;91(5):952–960. doi:10.1016/j.ijrobp.2015.01.002
   PubMed Web of Science ®Google Scholar
• Fountzilas G, Ciuleanu E, Bobos M, et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized Phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Ann Oncol. 2012;23(2):427–435. doi:10.1093/annonc/mdr116
   PubMed Web of Science ®Google Scholar
• Chen YP, Tang LL, Yang Q, et al. Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. Clin Cancer Res. 2018;24(8):1824–1833. doi:10.1158/1078-0432.CCR-17-2656
   PubMed Web of Science ®Google Scholar
• Tan TH, Soon YY, Cheo T, et al. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: a systematic review and meta-analysis. Radiother Oncol. 2018;129(1):10–17. doi:10.1016/j.radonc.2018.02.027
   PubMed Web of Science ®Google Scholar
• Ribassin-majed L, Marguet S, Lee A, et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol. 2017;35(5):498–505. doi:10.1200/JCO.2016.67.4119
   PubMed Web of Science ®Google Scholar
• Chen Y-P, Wang Y-Q, Li W-F, et al. Critical evaluation of the quality and recommendations of clinical practice guidelines for nasopharyngeal carcinoma. J Natl Compr Canc Netw. 2017;15(3):336–344. doi:10.6004/jnccn.2017.0033
   PubMed Web of Science ®Google Scholar
• Mao Y-P, Tang -L-L, Chen L, et al. Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy. Chin J Cancer. 2016;35(1):103. doi:10.1186/s40880-016-0167-2
   PubMedGoogle Scholar
• Peng H, Guo R, Chen L, et al. Prognostic impact of plasma Epstein-Barr virus DNA in patients with nasopharyngeal carcinoma treated using intensity-modulated radiation therapy. Sci Rep. 2016;6:22000. doi:10.1038/srep22000
   PubMed Web of Science ®Google Scholar
• Su S, Han F, Zhao C, et al. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone. Int J Rad Oncol Biol Phys. 2012;82(1):327–333. doi:10.1016/j.ijrobp.2010.09.011
   PubMed Web of Science ®Google Scholar
• Guo SS, Tang LQ, Chen QY, et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA >/=4000 copies/mL: a matched study. Oncotarget. 2016;7(20):29739.
   PubMedGoogle Scholar
• Du X-J, Tang L-L, Chen L, et al. Neoadjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: defining high-risk patients who may benefit before concurrent chemotherapy combined with intensity-modulated radiotherapy. Sci Rep. 2015;5:16664. doi:10.1038/srep16664
   PubMed Web of Science ®Google Scholar
• Chen Y, Guo R, Liu N, et al. Efficacy of the additional neoadjuvant chemotherapy to concurrent chemoradiotherapy for patients with locoregionally advanced nasopharyngeal carcinoma: a Bayesian network meta-analysis of randomized controlled trials. J Cancer. 2015;6(9):883–892. doi:10.7150/jca.11814
   PubMed Web of Science ®Google Scholar
• Chen YP, Wang ZX, Chen L, et al. A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Ann Oncol. 2015;26(1):205–211. doi:10.1093/annonc/mdu507
   PubMed Web of Science ®Google Scholar
• Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015;16(6):645–655. doi:10.1016/S1470-2045(15)70126-9
   PubMed Web of Science ®Google Scholar
• Li P, Mo H, Luo D, Hu W, Jin T. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era. Oral Oncol. 2018;85:95–100. doi:10.1016/j.oraloncology.2018.08.016
   PubMed Web of Science ®Google Scholar
• Hong RL, Hsiao CF, Ting LL, et al. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study. Ann Oncol. 2018;29(9):1972–1979. doi:10.1093/annonc/mdy249
   PubMed Web of Science ®Google Scholar
• Yao J, Jin Y, Liu Z, et al. Do all patients with advanced N-stage nasopharyngeal carcinoma benefit from the addition of induction chemotherapy to concurrent chemoradiotherapy? Ther Adv Med Oncol. 2019;11:386244890. doi:10.1177/1758835919833863
   Web of Science ®Google Scholar
• Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695–1704. doi:10.1056/NEJMoa071028
   PubMed Web of Science ®Google Scholar
• Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357(17):1705–1715. doi:10.1056/NEJMoa070956
   PubMed Web of Science ®Google Scholar
• Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009;101(7):498–506. doi:10.1093/jnci/djp007
   PubMed Web of Science ®Google Scholar
• Zhang LN, Gao YH, Lan XW, Tang J, OuYang PY, Xie FY. Effect of taxanes-based induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a large scale propensity-matched study. Oral Oncol. 2015;51(10):950–956. doi:10.1016/j.oraloncology.2015.07.004
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen M, Chen C, Kong L, Lu JJ, Xu B. The efficacy and toxicities of intensive induction chemotherapy followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma patients with N3 disease. Sci Rep-Uk. 2017;7:1.
   PubMed Web of Science ®Google Scholar
• Tang LQ, Chen QY, Fan W, et al. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol. 2013;31(23):2861–2869. doi:10.1200/JCO.2012.46.0816
   PubMed Web of Science ®Google Scholar
• Peng H, Chen L, Zhang Y, et al. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status. Oncotarget. 2016;7(17):24208–24216. doi:10.18632/oncotarget.v7i17
   PubMedGoogle Scholar
• Zhang J, Peng H, Li W, et al. Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma. BMC Cancer. 2018;18:1. doi:10.1186/s12885-018-5177-9
   PubMed Web of Science ®Google Scholar
• Xu C, Chen Y, Liu X, et al. Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy. Oral Oncol. 2017;69:99–107. doi:10.1016/j.oraloncology.2017.04.015
   PubMed Web of Science ®Google Scholar
• Denkert C, von Minckwitz G, Darb-esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40–50. doi:10.1016/S1470-2045(17)30904-X
   PubMed Web of Science ®Google Scholar
• Wang JT, Li H, Zhang H, et al. Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer. Ann Oncol. 2019;30(2):266–273. doi:10.1093/annonc/mdy505
   PubMed Web of Science ®Google Scholar
• Fu H, Zhu Y, Wang Y, et al. Identification and validation of stromal immunotype predict survival and benefit from adjuvant chemotherapy in patients with muscle-invasive bladder cancer. Clin Cancer Res. 2018;24(13):3069–3078. doi:10.1158/1078-0432.CCR-17-2687
   PubMed Web of Science ®Google Scholar